Efficacy and safety of anticancer drug combinations: a meta-analysis of randomized trials with a focus on immunotherapeutics and gene-targeted compounds
Hundreds of trials are being conducted to evaluate combination of newer targeted drugs as well as immunotherapy. Our aim was to compare efficacy and safety of combination versus single non-cytotoxic anticancer agents. We searched PubMed (01/01/2001 to 03/06/2018) (and, for immunotherapy, ASCO and ES...
Main Authors: | Denis L. Jardim, Débora De Melo Gagliato, Mina Nikanjam, Donald A. Barkauskas, Razelle Kurzrock |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2020-01-01
|
Series: | OncoImmunology |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/2162402X.2019.1710052 |
Similar Items
-
Dosing immunotherapy combinations: Analysis of 3,526 patients for toxicity and response patterns
by: Mina Nikanjam, et al.
Published: (2017-08-01) -
Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy
by: Yiyi Yan, et al.
Published: (2018-07-01) -
Advances in locoregional therapy for hepatocellular carcinoma combined with immunotherapy and targeted therapy
by: Jian Xue, et al.
Published: (2021-08-01) -
Systemic Cancer Therapy:
by: Michael Ostario Palumbo, et al.
Published: (2013-05-01) -
Novel Combination Therapies for the Treatment of Bladder Cancer
by: Mei Peng, et al.
Published: (2021-01-01)